KLTO (anewmeds.com) Market Value to Book Value Ratio
This daily price chart for Klotho Neurosciences Inc (KLTO) reflects the performance of a company developing dementia medications. Its yield stands at 3.67, while the business relies on an autonomous production cycle independent of global crises. The project's success is based on the exclusivity of scientific research into the Klotho protein, and its environmental strategy focuses on the careful handling of bioinformation.
%20Capitalization%20to%20Book%20Value%20Ratio&width=1200&height=400&colorIndex=0&v=mvrk6wqv.ssk-7as46ww&start=20220704&end=20261028&filename=GURU_Markets_-_KLTO_-_Klotho-Neurosciences-Inc_-_Capitalization-to-Book-Value-Ratio "KLTO ANEW Medical, Inc. Market Capitalization to Book Value Ratio (09/18/2024 - 03/11/2026) | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for Klotho Neurosciences Inc (KLTO)
- price and consensus price forecast:
- market capitalization data:
- book capitalization data:
- debt and liquidity data:
Fundamental valuation:ANEW Medical - KLTO
The global potential of Klotho Neurosciences Inc (KLTO) patents to combat neurodegeneration drives a high market value for its assets. The current price-to-book ratio reflects the relationship between the company's market capitalization and the value of its net assets. This metric measures the premium investors are willing to pay for the future scalability of the business. Steady growth in this indicator confirms market confidence in the commercial success of the innovative formulas. The trend of this indicator determines the fundamental margin of safety for the investment.
Direct competitors
Market Value to Book Value Ratio BIIB|NBIX (neurocrine.com) - Market-to-Book Ratio|Market Value to Book Value Ratio Regencell Bioscience Holdings Limited (RGC)|Capitalization to Book Value Ratio Axsome|ACADIA Pharmaceuticals Inc - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Xenon Corp XENE|Market Cap to Net Assets Ratio VKTX (Viking Therapeutics)|supernus.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Catalyst Pharmaceuticals, Inc. (CPRX)|DNLI: Market Value to Book Value|Market Value to Book Value Ratio HRMY|BHVN (Biohaven Corp) - Market-to-Book Ratio|AMLX (Amylyx Pharmaceuticals) - Market Value to Book Value Ratio|Market Capitalization to Book Value Ratio TRVI|Market Value to Book Value Ratio Praxis Precision Medicines, Inc. (PRAX)|Market Value to Book Value Ratio AVXL (Anavex)|CBLL: Market Value to Book Value Ratio|PRTA - Market-to-Book Ratio|Market Cap to Net Assets Ratio Alector Therapeutics ALEC|ANNX - Market Cap to Book Value Multiple|Market Capitalization to Book Value Ratio omeros.com OMER|NGNE (Neurogene Inc) - Market Value to Book Value|Market Value to Book Value Ratio ACIU (AC Immune Corp)|Market-to-Book Ratio Voyager Corp (VYGR)|Neumora Therapeutics (NMRA) - Market Cap to Net Assets Ratio|Market Value to Book Value SCLX (scilexholding.com)|TVGN - Market Value to Book Value Ratio|Capitalization to Book Value Ratio Alpha Cognition Inc ACOG|CGTX (Cognition Therapeutics, Inc.) - Market Capitalization to Book Value Ratio|Inhibikase Pharma (IKT) - Market-to-Book Ratio|SAVA: Market Cap to Net Assets Ratio|ASRT (Assertio) - Market Capitalization to Book Value Ratio|COYA - Market Value to Book Value Ratio|Market Value to Book Value VTGN|Ovid Therapeutics Inc. - Market Value to Book Value Ratio|Market-to-Book Ratio ABOS (Acumen Pharmaceuticals, Inc)|Market Value to Book Value Ratio CRVO|Market Capitalization to Book Value Alterity Therapeutics Ltd. ATHE|CLNN: Market Capitalization to Book Value Ratio|PEPG - Market Cap to Net Assets Ratio|Jupiter Neurosciences - Market Capitalization to Book Value Ratio|Relmada Corp (RLMD) - Market Capitalization to Book Value|Market Capitalization to Book Value Ratio ANVS (Annovis Bio, Inc.)|Market-to-Book Ratio GRCE|Market Value to Book Value Ratio Firefly Neuroscience AIFF|Capitalization to Book Value Ratio neurosense-tx.com (NRSN)|Reviva Pharmaceuticals Holdings - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio MetaVia Inc. MTVA|NRXS (NeurAxis, Inc.) - Market Capitalization to Book Value Ratio|HSDT: Market-to-Book Ratio|passagebio.com - Market Value to Book Value Ratio|Market Capitalization to Book Value Neuphoria Therapeutics|NERV - Market Cap to Net Assets Ratio|Market Value to Book Value Athira Pharma Corp|ADXN (Addex Therapeutics) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value ALZN (alzamend.com)|CYCN - Market Value to Book Value Ratio|Capitalization to Book Value Ratio Protagenic Therapeutics Inc. PTIX|KTTA: Market Capitalization to Book Value Ratio|CRGT: Market Cap to Net Assets Ratio|ATXI: Market Value to Book Value Ratio|BCLI (brainstorm-cell.com) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Cara Therapeutics|Market Value to Book Value Ratio Chromocell Therapeutics Corp (CHRO)|Market Cap to Net Assets Ratio Eliem Therapeutics|Market Cap to Book Value Multiple ITCI (intracellulartherapies.com)|LBPH: Market Value to Book Value Ratio|marinuspharma.com - Market-to-Book Ratio|NKGen Biotech (NKGN) - Market Value to Book Value Ratio|NRBO - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio SAGE|Market-to-Book Ratio Synaptogenix, Inc|TRVN (Trevena, Inc.) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio VIGL|Anew Medical, Inc. (WENA) - Market Value to Book Value Ratio|Market Value to Book Value CERE (Cerevel Therapeutics Inc)